Temoporfin

Overview

Temoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck . It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan.

Indication

For use in the treatment of patients with advanced squamous cell carcinoma of the head and neck failing standard therapies and who are unsuitable for radiotherapy, surgery, or systemic chemotherapy .

Associated Conditions

Advanced squamous cell carcinoma of the head and neck

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers	2016/12/26	NCT03003065	Phase 2	Completed	Chinese University of Hong Kong
Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery	2013/05/15	NCT01854684	Phase 1	Completed	Roswell Park Cancer Institute
Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer	2012/10/31	NCT01718223	Not Applicable	Withdrawn	Roswell Park Cancer Institute
Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer	2012/07/11	NCT01637376	Phase 1	Withdrawn	University of Arkansas
Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers	2011/08/12	NCT01415986	Phase 2	Terminated	University of Arkansas
Foscan®-Mediated Photodynamic Therapy Versus Brachytherapy in Patients With Nasopharyngeal Carcinoma	2010/03/15	NCT01086488	Phase 2	UNKNOWN	Ministry of Health, Malaysia
Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma	2009/11/18	NCT01016002	Phase 2	UNKNOWN	University of Salzburg
Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy	2004/06/03	NCT00003856	Phase 2	UNKNOWN	Quintiles, Inc.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
Foscan	Biolitec Pharma Ltd,Otto-Schott-Str. 15,07745 Jena,Germany	Authorised	10/24/2001

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access